Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

abstract：:Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia unspecified (one case) or s-myelodysplastic syndrome (five cases) following treatment for a primary malignancy. B...

journal_title：Leukemia

authors： Secker-Walker LM,Moorman AV,Bain BJ,Mehta AB

更新日期：1998-05-01 00:00:00

abstract：:Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin s...

journal_title：Leukemia

authors： Chng WJ,Santana-Dávila R,Van Wier SA,Ahmann GJ,Jalal SM,Bergsagel PL,Chesi M,Trendle MC,Jacobus S,Blood E,Oken MM,Henderson K,Kyle RA,Gertz MA,Lacy MQ,Dispenzieri A,Greipp PR,Fonseca R

更新日期：2006-05-01 00:00:00

abstract：:A polymerase chain reaction analysis of biopsy specimens from a total of 52 patients with Hodgkin's disease has revealed the presence of the t(14;18) chromosomal translocation in 14 cases (28%). Twelve involved the major breakpoint region and two included the minor cluster region of the bcl-2 gene. Direct sequencing o...

journal_title：Leukemia

authors： Gupta RK,Lister TA,Bodmer JG

更新日期：1994-08-01 00:00:00

abstract：:In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

journal_title：Leukemia

authors： Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

更新日期：2014-06-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect...

journal_title：Leukemia

authors： Dubois C,Schlageter MH,de Gentile A,Balitrand N,Toubert ME,Krawice I,Fenaux P,Castaigne S,Najean Y,Degos L

更新日期：1994-10-01 00:00:00

abstract：:The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

journal_title：Leukemia

authors： Ames MM,Spreafico F

更新日期：1992-01-01 00:00:00

abstract：:Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. In order to investigate the status of the CDKN2 gene in cell lines established from childhood acute lymphoblastic leukemia (ALL), we surveyed 25 lines representing the maj...

journal_title：Leukemia

authors： Zhou M,Gu L,James CD,He J,Yeager AM,Smith SD,Findley HW

更新日期：1995-07-01 00:00:00

abstract：:RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

journal_title：Leukemia

authors： Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

更新日期：2020-03-01 00:00:00

abstract：:Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were...

journal_title：Leukemia

authors： Kumar SK,Lee JH,Lahuerta JJ,Morgan G,Richardson PG,Crowley J,Haessler J,Feather J,Hoering A,Moreau P,LeLeu X,Hulin C,Klein SK,Sonneveld P,Siegel D,Bladé J,Goldschmidt H,Jagannath S,Miguel JS,Orlowski R,Palumbo A,

更新日期：2012-01-01 00:00:00

abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

journal_title：Leukemia

authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

更新日期：2014-08-01 00:00:00

abstract：:RT-PCR assays used to detect acute promyelocytic leukemia (APL) are generally considered less sensitive than those for other hematological malignancies, such as CGL. Most patients with APL express del(17q)-derived RAR alpha-PML transcripts as well as the putative leukemogenic PML-RAR alpha associated with add(15q). We...

journal_title：Leukemia

authors： Grimwade D,Howe K,Langabeer S,Burnett A,Goldstone A,Solomon E

更新日期：1996-01-01 00:00:00

abstract：:We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age grou...

journal_title：Leukemia

authors： Reedijk AMJ,Coebergh JWW,de Groot-Kruseman HA,van der Sluis IM,Kremer LC,Karim-Kos HE,Pieters R

更新日期：2020-08-21 00:00:00

abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

journal_title：Leukemia

authors： Giles FJ,O'Dwyer M,Swords R

更新日期：2009-10-01 00:00:00

abstract：:Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma. The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combin...

journal_title：Leukemia

authors： Carney DA,Westerman DA,Tam CS,Milner A,Prince HM,Kenealy M,Wolf M,Januszewicz EH,Ritchie D,Came N,Seymour JF

更新日期：2010-12-01 00:00:00

abstract：:Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; ...

journal_title：Leukemia

authors： Poggi A,Catellani S,Garuti A,Pierri I,Gobbi M,Zocchi MR

更新日期：2009-04-01 00:00:00

abstract：:We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...

journal_title：Leukemia

authors： Caramazza D,Begna KH,Gangat N,Vaidya R,Siragusa S,Van Dyke DL,Hanson C,Pardanani A,Tefferi A

更新日期：2011-01-01 00:00:00

abstract：:The response of human acute myelogenous leukemia (AML) cells to four different hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 beta (IL-1beta), interleukin-3 (IL-3), and stem cell factor (SCF)) and the relationship of the proliferative response of the AML cells to...

journal_title：Leukemia

authors： Tsuzuki M,Ezaki K,Maruyama F,Ino T,Kojima H,Okamoto M,Yamaguchi T,Nomura T,Miyazaki H,Wakita M,Matsui T,Hirano M

更新日期：1997-12-01 00:00:00

abstract：:Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing differen...

journal_title：Leukemia

authors： Hegedus CM,Gunn L,Skibola CF,Zhang L,Shiao R,Fu S,Dalmasso EA,Metayer C,Dahl GV,Buffler PA,Smith MT

更新日期：2005-10-01 00:00:00

abstract：:Two pediatric cases of acute lymphoblastic leukemia with L1 morphology who also demonstrated immunoglobulin on the leukemic cell surface are presented. The first patient's disease progressed on standard induction therapy, despite the presence of good prognostic features at presentation. The second patient has achieved...

journal_title：Leukemia

authors： Finlay JL,Borcherding W

更新日期：1988-01-01 00:00:00

abstract：:Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, we applied RNA interference to silence TEL/AML1 in le...

journal_title：Leukemia

authors： Zaliova M,Madzo J,Cario G,Trka J

更新日期：2011-02-01 00:00:00

abstract：:A single dominant gene Tlsm-1 was found to determine the type of spontaneous lymphomas to be T in the cross between AKR/Ms and SL/Kh. Microsatellite analysis mapped Tlsm-1 at the position 61 cM from centromere of Chr. 7. Study of this segment of T-lymphoma prone AKXD Rl strains also showed association of Tlsm-1 with T...

journal_title：Leukemia

authors： Hiai H,Yamada Y,Shisa H,Kamoto T,Abujiang P,Lu LM

更新日期：1997-04-01 00:00:00

abstract：:We have investigated the function of C3b receptor (CR1) in the malignant lymphocytes of B-chronic lymphocytic leukemia (B-CLL) mimicking the physiological ligand C3b with the anti-CR1 monoclonal antibody CB04 covalently linked to Sepharose CL-4B (CB04-S). The binding of insolubilized CB04-S to CR1 gave a progression s...

journal_title：Leukemia

authors： Caligaris-Cappio F,Schena M,Bergui L,Tesio L,Riva M,Rege-Cambrin G,Funaro A,Malavasi F

更新日期：1987-11-01 00:00:00

abstract：:Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60,...

journal_title：Leukemia

authors： Naito K,Takeshita A,Shigeno K,Nakamura S,Fujisawa S,Shinjo K,Yoshida H,Ohnishi K,Mori M,Terakawa S,Ohno R

更新日期：2000-08-01 00:00:00

abstract：:A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. An international working group (WG) was convened to develop a consensus formulation of clinically significant criteria for defining resistance/intolerance to HU in ET. To this aim, ...

journal_title：Leukemia

authors： Barosi G,Besses C,Birgegard G,Briere J,Cervantes F,Finazzi G,Gisslinger H,Griesshammer M,Gugliotta L,Harrison C,Hasselbalch H,Lengfelder E,Reilly JT,Michiels JJ,Barbui T

更新日期：2007-02-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predic...

journal_title：Leukemia

authors： Asnafi V,Rubio MT,Delabesse E,Villar E,Davi F,Damaj G,Hirsch I,Dhédin N,Vernant JP,Varet B,Buzyn A,Macintyre E

更新日期：2006-05-01 00:00:00

abstract：:Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using...

journal_title：Leukemia

authors： Wierda WG,Castro JE,Aguillon R,Sampath D,Jalayer A,McMannis J,Prussak CE,Keating M,Kipps TJ

更新日期：2010-11-01 00:00:00

abstract：:The mechanisms by which non-oncogene bearing, slowly transforming T-cell-tropic retroviruses induce leukemia is not well understood. Viruses such as the murine radiation leukemia virus (RadLV) induce oncogenic transformation of T-cells in the thymus only in vivo and after a long latency. The capacity of RadLV to induc...

journal_title：Leukemia

authors： O'Neill HC

更新日期：1992-04-01 00:00:00

abstract：:The R98S mutation in ribosomal protein L10 (RPL10 R98S) affects 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases, and was previously described to impair cellular proliferation. The current study reveals that RPL10 R98S cells accumulate reactive oxygen species which promotes mitochondrial dysfunction a...

journal_title：Leukemia

authors： Kampen KR,Sulima SO,Verbelen B,Girardi T,Vereecke S,Rinaldi G,Verbeeck J,Op de Beeck J,Uyttebroeck A,Meijerink JPP,Moorman AV,Harrison CJ,Spincemaille P,Cools J,Cassiman D,Fendt SM,Vermeersch P,De Keersmaecker K

更新日期：2019-02-01 00:00:00

abstract：:Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

journal_title：Leukemia

authors： Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

更新日期：2013-12-01 00:00:00

abstract：:We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

journal_title：Leukemia

authors： Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

更新日期：1998-07-01 00:00:00